Berlin, Germany
Berlin, Germany

MagForce Nanotechnologies AG is a German biotechnology company focusing on cancer treatment. It is a world's leading company in treating cancer cells with nanotechnology-based therapy. The company is led by CEO Ben J. Lipps. Wikipedia.


Time filter

Source Type

The invention relates to a computer-aided simulation tool, in particular to computer-aided simulation methods, for providing assistance in the planning of thermotherapy, and to suitably configured computer equipment. The thermotherapy comprises hyperthermic treatment of a tumour volume within a volume of a human body. The hyperthermic treatment comprises the application of a magnetic field within a treatment volume by means of a magnetic field applicator. In at least one depot volume, thermal energy can be introduced by means of magnetic, paramagnetic and/or superparamagnetic nanoparticles deposited in the body, by power absorption in the applied magnetic field. Field strength values and optionally calculated temperature distributions are provided for assisting the user in the planning of the thermotherapy.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.1.2-1 | Award Amount: 10.28M | Year: 2013

Microbubbles (MBs) are used as contrast agent in ultrasound (US) imaging for a variety of tumours while little has been done for glioblastomas, a rare cancer. Intraoperative Contrast-Enhanced US-imaging (CEUS) using lipidic MBs hold promises in increasing extent of resection of such tumors. Furthermore, MBs gained recently interest as a delivery system for drugs. We will develop a new generation of multimodal MBs, acting simultaneously as contrast agent for Magnetic Resonance Imaging (MRI), CEUS and intra-operative fluorescence for multimodal real-time image-guided resection of glioblastomas. We plan to transform MBs by replacing air with perfluorcarbon gas and/or attaching super-paramagnetic-iron-oxide nanoparticles for MRI visualization. We will also engineer MBs with RGD-motif to adhere selectively to pathological endothelial integrins and with near-infrared fluorophores for simultaneous US deep tissue imaging and direct microscopic tumour visualization to maximize resection. A software will be developed for integration of preoperative MRI, intraoperative US and microscopic imaging. We will focus on lipidic and polymeric MBs. Lipidic MBs are approved for clinical use; therefore, once modified, more easily translatable into clinical applications to reach a feasibility study on patients. In addition, we will improve multifunctional, polymer-based MBs. Multifunctional-stabilized-polymer-MBs are more stable and more versatile to be complexed with different molecules or nanoparticles as compared to lipidic Mbs and will be designed as a platform for delivering standard and/or experimental chemotherapeutic drugs to the tumour, acting as an innovative way for local targeting and delivering any kind of agent to a specific target, in a safe and controlled fashion. This would be a big step forward in the field of personalized medicine, moving standard MG image-guided treatment towards more effective, safer, molecular-based tailored interventions to specific patients.


The present invention relates to a method for producing a suspension of agglomerates of magnetic alkoxysilane-coated metal nanoparticles, wherein an aqueous suspension of magnetic metal nanoparticles is incubated with alkoxysilane, wherein the incubation is carried out essentially in the absence of an organic solvent. The present invention further relates to suspension of agglomerates of magnetic alkoxysilane-coated metal containing nanoparticles obtainable by the method of the present invention and to a composition comprising agglomerates of magnetic alkoxysilane-coated metal nanoparticles, wherein the agglomerates have an average size of 30 to 450 nm, preferably of 50 to 350 nm and especially of 70 to 300 nm as determined by light scattering.


Patent
MagForce | Date: 2014-05-15

Embodiments herein relate to the production of biocompatible magnetic nanoparticles with a high SAR-value which produce a large amount of heat when exposed to an alternating magnetic field. The produced heat can be used among others for therapeutic purposes, in particular for combating cancer.


The present invention relates to a method for producing a suspension of agglomerates of magnetic alkoxysilane-coated metal nanoparticles, wherein an aqueous suspension of magnetic metal nanoparticles is incubated with alkoxysilane, wherein the incubation is carried out essentially in the absence of an organic solvent. The present invention further relates to suspension of agglomerates of magnetic alkoxysilane-coated metal containing nanoparticles obtainable by the method of the present invention and to a composition comprising agglomerates of magnetic alkoxysilane-coated metal nanoparticles, wherein the agglomerates have an average size of 30 to 450 nm, preferably of 50 to 350 nm and especially of 70 to 300 nm as determined by light scattering.


Patent
MagForce | Date: 2015-09-09

The present invention relates to compositions containing nanoparticies and uses of said composition for transferring therapeutically active substances into cells by means of specifically coated nanoparticles. The chemical design of the particles is such that a large amount thereof is absorbed into the cells. No direct bond between nanoparticle and the therapeutically active substance is required for the transfer into the cells. Thanks to said transfer, an increased efficacy of the substance and simultaneously reduced systemic toxicity is achieved, i.e. an increase in the efficacy while the side effects are reduced.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: NMP-2008-1.1-1 | Award Amount: 4.86M | Year: 2009

The aim of this project is the assembly and the fabrication of a new generation of multifunctional nanostructures for performing combined hyperthermia and controlled drug release, specifically targeted to cancer cells. The magnetic nanocontainers we intend to develop can perform at the same time cell recognition, hyperthermia treatment, and, as a consequence of the heat and /or cell environment stimuli, the release of drug with high selectivity for ovarian carcinoma. These multifunctional tasks are made possible due to the inclusion of three main components: a) the magnetic nanoparticles, allowing detection by MRI, cancer treatment by hyperthermia and providing stimuli for drug release; b) the nanocontainers, which allow for drug encapsulation and protection from degradation, facilitate the release of the drug upon application of an external stimulus, such as heat, or an internal one, such as the acidic pH of the tumour cells; c) the antibody fragments attached to the surface of the magnetic nanocontainers to deliver them selectively to the ovarian cancer cells. The individual building blocks and their assemblies will be characterized with respect to physical, chemical, and biological features, followed by dissemination of the newly acquired knowledge. Cell culture experiments will allow to understand the performance of such nano-tools in vitro. Directed towards application in patients, in vivo animal studies will be carried out on the most successful magnetic nanocontainers. The objectives of this proposal cover a wide range of scientific fields, hence a truly interdisciplinary collaboration between chemists, physicists, and biologists is required. To this end, we propose a european network collaboration between academic partners, who will take care of the development of new solutions for nanofabrication, and industrial partners implied in the field of the proposed application who will evaluate/develop the materials and act as advisors for risks arising during the project.


News Article | March 2, 2017
Site: www.accesswire.com

BERLIN, GERMANY, AND NEVADA / ACCESSWIRE / March 2, 2017 / MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today published its first Shareholder Letter 2017: Since the publication of our last Shareholder Letter, we have continued our joint efforts on both of our defined paths to create additional shareholder value: Path 2: Treatment of intermediate risk prostate cancer in the USA We are pleased to give you an interim update on the respective developments. MagForce AG is continuing to expand the commercialization of its innovative NanoTherm(R) therapy. We successfully installed NanoActivator(R) devices in 2014 and 2015 in Germany to assist the neurosurgeons and radiologists as they became familiar with our NanoTherm(R) therapy and its applicability. In their quest to improve patient care, the neurosurgeons applying NanoTherm(R) therapy to the treatment of brain tumors continue to find additional medical benefits when NanoTherm(R) therapy is incorporated into their usual treatment regimen. Such a positive finding for example was described by Dr. med. Johannes Wölfer, Deputy Director of the Neurosurgical Department, Clinic and Policlinic for Neurosurgery, University Hospital Münster and part of the team of Prof. Dr. med. Walter Stummer, Director of the Department of Neurosurgery at the University Hospital Münster and President of the German Neurosurgical Society (DGNC), as described in our press release as of December 2, 2016. Since the last Shareholder Letter we presented at the following conferences and congresses: MagForce's participation in these conferences and congresses increases the awareness of our unique therapy within the main target groups, such as patient advocacy groups, patients, their relatives, caregivers, and the medical community. We increasingly receive positive feedback from patients regarding their experiences with our NanoTherm(R) therapy. These examples, one of which we are showing in a new video on our website http://www.magforce.de/en/home.html are an important driver for the commercialization of our innovative therapy. During 2016, we have streamlined the implementation of the cross-border reimbursement process, however, due to the aggressiveness of glioblastoma, there is a limited time interval to achieve treatment. In order to give patients the benefit from our NanoTherm(R) treatment, we will continue to increase the medical awareness of the value of NanoTherm(R) therapy to encourage patients and neurosurgeons to consider NanoTherm(R) therapy earlier following the diagnosis of their tumor status. Further, we have developed a European roll-out plan, anticipating treatment centers in selected European countries to allow patient treatment in their home countries. From this approach we expect advantages in the areas of reimbursement and timely availability of NanoTherm(R) therapy. At the same time, we are in the process of obtaining domestic reimbursement for NanoTherm(R) therapy in Germany and we are preparing the same for those selected countries in the EU where MagForce has the CE Mark for the treatment of brain tumors. Our commercial and medical teams have identified the respective countries and clinics which qualify as NanoTherm(R) treatment centers. Based on the very gratifying medical results, management is confident that the European expansion starting in 2017, when combined with reimbursement approval in these countries, will significantly speed up revenue and profit generation in Europe. Treatment of intermediate risk prostate cancer in the USA: MagForce USA, Inc. in 2015, filed an Investigational Device Exemption (IDE) with the USA Food and Drug Administration (FDA) for NanoTherm(R) therapy to treat Intermediate Risk Prostate Cancer. Our objective with this early filing was to obtain FDA guidance as to their required pre-clinical studies to allow a pivotal clinical evaluation with our innovative and unknown NanoTherm(R) therapy. During 2016, MagForce USA repeated and updated its pre-clinical studies, which were previously conducted in Germany approximately ten years ago, at the recommendation of the FDA. MagForce USA repeated all of the previous biocompatibility studies designed to assess the toxicity and possible migration of MagForce's nanoparticles once instilled into the prostate. These studies again confirmed the lack of toxicity and lack of migration of the nanoparticles. The results of these pre-clinical studies and the proposed clinical trial protocol were submitted to the FDA in late fourth quarter, 2016. An in-person follow-up meeting with FDA representatives was held in early January, 2017 to discuss MagForce's submissions and identify required clarification. This meeting was again very productive and MagForce believes we can successfully address their questions. While we are now approximately three months behind our schedule, we are still confident and will make every effort to achieve our original targets in terms of market entry and commercialization of NanoTherm(R) therapy in the USA - which is projected for early 2018. The key to achieving our goals is to continue to establish our clinical treatment sites and obtain the necessary approvals to treat patients. After having announced Seattle Washington in 2015 for pre-clinical and clinical studies, we have now identified a second planned site to exclusively participate in the pivotal clinical studies. In addition to our lead site at The University of Washington in Seattle, Washington, our second site is now located at CHRISTUS Santa Rosa Hospital - Medical Center in San Antonio, Texas. Ian M. Thompson Jr., MD, our Co-Principle Investigator, has been newly appointed as President of CHRISTUS Santa Rosa Hospital - Medical Center among his many responsibilities. This clinical site will encompass both a clinical office and the NanoActivator(R) treatment center. CHRISTUS Santa Rosa Health is an international Catholic, faith-based, not-for-profit health system, and comprised of over 500 services and facilities, including more than 50 hospitals and long-term facilities and 275 clinics and outpatient centers. CHRISTUS Santa Rosa's services can be found in over 100 cities in the United States, Chile, Mexico and Colombia, and employs over 40,000 associates and has more than 10,000 physicians on medical staff. We are very excited to work with the team of CHRISTUS Santa Rosa Hospital - Medical Center with its exceptional experience and knowledge. This partnership also gives MagForce the potential to utilize CHRISTUS Santa Rosa's established network once the FDA approval is obtained and our partners at CHRISTUS Santa Rosa Hospital - Medical Center are satisfied with the treatment regimen. MagForce's management is pursuing non/low dilutive financing options to reach our European expansion goals. In addition, in order to bolster liquidity and facilitate new product development beyond 2017, we have issued a three-year convertible note. Product development includes laying the groundwork for expanding MagForce's therapy to additional tumors, like brain metastasis, and to also use our nano-particles as a drug delivery mechanism. The note is in the amount of EUR 5 million, will bear an interest rate at 5% p.a. and have a conversion price at 5,00 EUR/share. The note has been issued to an investment vehicle managed by Lansdowne Partners Austria. Dear Shareholders, we are very grateful for your continuous support of our efforts, and we are very confident that 2017 will turn out to be the best and most defining year in the history of MagForce. About MagForce AG and MagForce USA, Inc. MagForce AG, listed in the new Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(R) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc. NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries. For more information, please visit: www.magforce.com. Get to know our Technology: video (You Tube) Stay informed and subscribe to our mailing list. This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated. SOURCE: MagForce AG via the EQS Newswire distribution service including Press Releases and Regulatory Announcements


News Article | March 2, 2017
Site: marketersmedia.com

Speeding up of European Expansion US Commercialization expected to start early 2018​ Issuance of Convertible, subscribed by Lansdowne Partners Austria BERLIN, GERMANY, AND NEVADA / ACCESSWIRE / March 2, 2017 / MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today published its first Shareholder Letter 2017: Since the publication of our last Shareholder Letter, we have continued our joint efforts on both of our defined paths to create additional shareholder value: Path 2: Treatment of intermediate risk prostate cancer in the USA We are pleased to give you an interim update on the respective developments. MagForce AG is continuing to expand the commercialization of its innovative NanoTherm(R) therapy. We successfully installed NanoActivator(R) devices in 2014 and 2015 in Germany to assist the neurosurgeons and radiologists as they became familiar with our NanoTherm(R) therapy and its applicability. In their quest to improve patient care, the neurosurgeons applying NanoTherm(R) therapy to the treatment of brain tumors continue to find additional medical benefits when NanoTherm(R) therapy is incorporated into their usual treatment regimen. Such a positive finding for example was described by Dr. med. Johannes Wölfer, Deputy Director of the Neurosurgical Department, Clinic and Policlinic for Neurosurgery, University Hospital Münster and part of the team of Prof. Dr. med. Walter Stummer, Director of the Department of Neurosurgery at the University Hospital Münster and President of the German Neurosurgical Society (DGNC), as described in our press release as of December 2, 2016. Since the last Shareholder Letter we presented at the following conferences and congresses: 13th AIO Autumn Convention - Oncology in Internal Medicine Working Group (AIO) - Update Medical Oncology - November 17-19, 2016, Berlin 21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) - November 17-20, 2016, Scottsdale, Arizona Presentation: "Inflammatory response after modified NanoTherm(R) and radiotherapy of recurrent glioblastoma" Presenter: Team of Prof. Dr. med. Walter Stummer, Director of the Clinic for Neurosurgery, University Hospital Münster Speaker: Dr. Dr. med. Oliver Grauer, Head of Neuro-Oncology Team, University Hospital Münster NOA Winter School 2016 - Neuro-oncological Working Group - December 1-2, 2016, Münster Presentation: "Local Hyperthermia as an adjuvant for malignant glioblastoma - NanoTherm and NanoPaste" Speaker: Dr. med. Johannes Wölfer, Deputy Director of the Neurosurgical Department, Clinic and Policlinic for Neurosurgery, University Hospital Münster European CanCer Organization (ECCO) - January 27-30, 2017, Amsterdam MagForce's participation in these conferences and congresses increases the awareness of our unique therapy within the main target groups, such as patient advocacy groups, patients, their relatives, caregivers, and the medical community. We increasingly receive positive feedback from patients regarding their experiences with our NanoTherm(R) therapy. These examples, one of which we are showing in a new video on our website http://www.magforce.de/en/home.html, are an important driver for the commercialization of our innovative therapy. During 2016, we have streamlined the implementation of the cross-border reimbursement process, however, due to the aggressiveness of glioblastoma, there is a limited time interval to achieve treatment. In order to give patients the benefit from our NanoTherm(R) treatment, we will continue to increase the medical awareness of the value of NanoTherm(R) therapy to encourage patients and neurosurgeons to consider NanoTherm(R) therapy earlier following the diagnosis of their tumor status. Further, we have developed a European roll-out plan, anticipating treatment centers in selected European countries to allow patient treatment in their home countries. From this approach we expect advantages in the areas of reimbursement and timely availability of NanoTherm(R) therapy. At the same time, we are in the process of obtaining domestic reimbursement for NanoTherm(R) therapy in Germany and we are preparing the same for those selected countries in the EU where MagForce has the CE Mark for the treatment of brain tumors. Our commercial and medical teams have identified the respective countries and clinics which qualify as NanoTherm(R) treatment centers. Based on the very gratifying medical results, management is confident that the European expansion starting in 2017, when combined with reimbursement approval in these countries, will significantly speed up revenue and profit generation in Europe. Treatment of intermediate risk prostate cancer in the USA: MagForce USA, Inc. in 2015, filed an Investigational Device Exemption (IDE) with the USA Food and Drug Administration (FDA) for NanoTherm(R) therapy to treat Intermediate Risk Prostate Cancer. Our objective with this early filing was to obtain FDA guidance as to their required pre-clinical studies to allow a pivotal clinical evaluation with our innovative and unknown NanoTherm(R) therapy. During 2016, MagForce USA repeated and updated its pre-clinical studies, which were previously conducted in Germany approximately ten years ago, at the recommendation of the FDA. MagForce USA repeated all of the previous biocompatibility studies designed to assess the toxicity and possible migration of MagForce's nanoparticles once instilled into the prostate. These studies again confirmed the lack of toxicity and lack of migration of the nanoparticles. The results of these pre-clinical studies and the proposed clinical trial protocol were submitted to the FDA in late fourth quarter, 2016. An in-person follow-up meeting with FDA representatives was held in early January, 2017 to discuss MagForce's submissions and identify required clarification. This meeting was again very productive and MagForce believes we can successfully address their questions. While we are now approximately three months behind our schedule, we are still confident and will make every effort to achieve our original targets in terms of market entry and commercialization of NanoTherm(R) therapy in the USA - which is projected for early 2018. The key to achieving our goals is to continue to establish our clinical treatment sites and obtain the necessary approvals to treat patients. After having announced Seattle Washington in 2015 for pre-clinical and clinical studies, we have now identified a second planned site to exclusively participate in the pivotal clinical studies. In addition to our lead site at The University of Washington in Seattle, Washington, our second site is now located at CHRISTUS Santa Rosa Hospital - Medical Center in San Antonio, Texas. Ian M. Thompson Jr., MD, our Co-Principle Investigator, has been newly appointed as President of CHRISTUS Santa Rosa Hospital - Medical Center among his many responsibilities. This clinical site will encompass both a clinical office and the NanoActivator(R) treatment center. CHRISTUS Santa Rosa Health is an international Catholic, faith-based, not-for-profit health system, and comprised of over 500 services and facilities, including more than 50 hospitals and long-term facilities and 275 clinics and outpatient centers. CHRISTUS Santa Rosa's services can be found in over 100 cities in the United States, Chile, Mexico and Colombia, and employs over 40,000 associates and has more than 10,000 physicians on medical staff. We are very excited to work with the team of CHRISTUS Santa Rosa Hospital - Medical Center with its exceptional experience and knowledge. This partnership also gives MagForce the potential to utilize CHRISTUS Santa Rosa's established network once the FDA approval is obtained and our partners at CHRISTUS Santa Rosa Hospital - Medical Center are satisfied with the treatment regimen. MagForce's management is pursuing non/low dilutive financing options to reach our European expansion goals. In addition, in order to bolster liquidity and facilitate new product development beyond 2017, we have issued a three-year convertible note. Product development includes laying the groundwork for expanding MagForce's therapy to additional tumors, like brain metastasis, and to also use our nano-particles as a drug delivery mechanism. The note is in the amount of EUR 5 million, will bear an interest rate at 5% p.a. and have a conversion price at 5,00 EUR/share. The note has been issued to an investment vehicle managed by Lansdowne Partners Austria. Dear Shareholders, we are very grateful for your continuous support of our efforts, and we are very confident that 2017 will turn out to be the best and most defining year in the history of MagForce. About MagForce AG and MagForce USA, Inc. MagForce AG, listed in the new Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(R) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc. NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries. For more information, please visit: www.magforce.com. Get to know our Technology: video (You Tube) Stay informed and subscribe to our mailing list. This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated. SOURCE: MagForce AG via the EQS Newswire distribution service including Press Releases and Regulatory Announcements Speeding up of European Expansion US Commercialization expected to start early 2018​ Issuance of Convertible, subscribed by Lansdowne Partners Austria BERLIN, GERMANY, AND NEVADA / ACCESSWIRE / March 2, 2017 / MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today published its first Shareholder Letter 2017: Since the publication of our last Shareholder Letter, we have continued our joint efforts on both of our defined paths to create additional shareholder value: Path 2: Treatment of intermediate risk prostate cancer in the USA We are pleased to give you an interim update on the respective developments. MagForce AG is continuing to expand the commercialization of its innovative NanoTherm(R) therapy. We successfully installed NanoActivator(R) devices in 2014 and 2015 in Germany to assist the neurosurgeons and radiologists as they became familiar with our NanoTherm(R) therapy and its applicability. In their quest to improve patient care, the neurosurgeons applying NanoTherm(R) therapy to the treatment of brain tumors continue to find additional medical benefits when NanoTherm(R) therapy is incorporated into their usual treatment regimen. Such a positive finding for example was described by Dr. med. Johannes Wölfer, Deputy Director of the Neurosurgical Department, Clinic and Policlinic for Neurosurgery, University Hospital Münster and part of the team of Prof. Dr. med. Walter Stummer, Director of the Department of Neurosurgery at the University Hospital Münster and President of the German Neurosurgical Society (DGNC), as described in our press release as of December 2, 2016. Since the last Shareholder Letter we presented at the following conferences and congresses: 13th AIO Autumn Convention - Oncology in Internal Medicine Working Group (AIO) - Update Medical Oncology - November 17-19, 2016, Berlin 21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) - November 17-20, 2016, Scottsdale, Arizona Presentation: "Inflammatory response after modified NanoTherm(R) and radiotherapy of recurrent glioblastoma" Presenter: Team of Prof. Dr. med. Walter Stummer, Director of the Clinic for Neurosurgery, University Hospital Münster Speaker: Dr. Dr. med. Oliver Grauer, Head of Neuro-Oncology Team, University Hospital Münster NOA Winter School 2016 - Neuro-oncological Working Group - December 1-2, 2016, Münster Presentation: "Local Hyperthermia as an adjuvant for malignant glioblastoma - NanoTherm and NanoPaste" Speaker: Dr. med. Johannes Wölfer, Deputy Director of the Neurosurgical Department, Clinic and Policlinic for Neurosurgery, University Hospital Münster European CanCer Organization (ECCO) - January 27-30, 2017, Amsterdam MagForce's participation in these conferences and congresses increases the awareness of our unique therapy within the main target groups, such as patient advocacy groups, patients, their relatives, caregivers, and the medical community. We increasingly receive positive feedback from patients regarding their experiences with our NanoTherm(R) therapy. These examples, one of which we are showing in a new video on our website http://www.magforce.de/en/home.html, are an important driver for the commercialization of our innovative therapy. During 2016, we have streamlined the implementation of the cross-border reimbursement process, however, due to the aggressiveness of glioblastoma, there is a limited time interval to achieve treatment. In order to give patients the benefit from our NanoTherm(R) treatment, we will continue to increase the medical awareness of the value of NanoTherm(R) therapy to encourage patients and neurosurgeons to consider NanoTherm(R) therapy earlier following the diagnosis of their tumor status. Further, we have developed a European roll-out plan, anticipating treatment centers in selected European countries to allow patient treatment in their home countries. From this approach we expect advantages in the areas of reimbursement and timely availability of NanoTherm(R) therapy. At the same time, we are in the process of obtaining domestic reimbursement for NanoTherm(R) therapy in Germany and we are preparing the same for those selected countries in the EU where MagForce has the CE Mark for the treatment of brain tumors. Our commercial and medical teams have identified the respective countries and clinics which qualify as NanoTherm(R) treatment centers. Based on the very gratifying medical results, management is confident that the European expansion starting in 2017, when combined with reimbursement approval in these countries, will significantly speed up revenue and profit generation in Europe. Treatment of intermediate risk prostate cancer in the USA: MagForce USA, Inc. in 2015, filed an Investigational Device Exemption (IDE) with the USA Food and Drug Administration (FDA) for NanoTherm(R) therapy to treat Intermediate Risk Prostate Cancer. Our objective with this early filing was to obtain FDA guidance as to their required pre-clinical studies to allow a pivotal clinical evaluation with our innovative and unknown NanoTherm(R) therapy. During 2016, MagForce USA repeated and updated its pre-clinical studies, which were previously conducted in Germany approximately ten years ago, at the recommendation of the FDA. MagForce USA repeated all of the previous biocompatibility studies designed to assess the toxicity and possible migration of MagForce's nanoparticles once instilled into the prostate. These studies again confirmed the lack of toxicity and lack of migration of the nanoparticles. The results of these pre-clinical studies and the proposed clinical trial protocol were submitted to the FDA in late fourth quarter, 2016. An in-person follow-up meeting with FDA representatives was held in early January, 2017 to discuss MagForce's submissions and identify required clarification. This meeting was again very productive and MagForce believes we can successfully address their questions. While we are now approximately three months behind our schedule, we are still confident and will make every effort to achieve our original targets in terms of market entry and commercialization of NanoTherm(R) therapy in the USA - which is projected for early 2018. The key to achieving our goals is to continue to establish our clinical treatment sites and obtain the necessary approvals to treat patients. After having announced Seattle Washington in 2015 for pre-clinical and clinical studies, we have now identified a second planned site to exclusively participate in the pivotal clinical studies. In addition to our lead site at The University of Washington in Seattle, Washington, our second site is now located at CHRISTUS Santa Rosa Hospital - Medical Center in San Antonio, Texas. Ian M. Thompson Jr., MD, our Co-Principle Investigator, has been newly appointed as President of CHRISTUS Santa Rosa Hospital - Medical Center among his many responsibilities. This clinical site will encompass both a clinical office and the NanoActivator(R) treatment center. CHRISTUS Santa Rosa Health is an international Catholic, faith-based, not-for-profit health system, and comprised of over 500 services and facilities, including more than 50 hospitals and long-term facilities and 275 clinics and outpatient centers. CHRISTUS Santa Rosa's services can be found in over 100 cities in the United States, Chile, Mexico and Colombia, and employs over 40,000 associates and has more than 10,000 physicians on medical staff. We are very excited to work with the team of CHRISTUS Santa Rosa Hospital - Medical Center with its exceptional experience and knowledge. This partnership also gives MagForce the potential to utilize CHRISTUS Santa Rosa's established network once the FDA approval is obtained and our partners at CHRISTUS Santa Rosa Hospital - Medical Center are satisfied with the treatment regimen. MagForce's management is pursuing non/low dilutive financing options to reach our European expansion goals. In addition, in order to bolster liquidity and facilitate new product development beyond 2017, we have issued a three-year convertible note. Product development includes laying the groundwork for expanding MagForce's therapy to additional tumors, like brain metastasis, and to also use our nano-particles as a drug delivery mechanism. The note is in the amount of EUR 5 million, will bear an interest rate at 5% p.a. and have a conversion price at 5,00 EUR/share. The note has been issued to an investment vehicle managed by Lansdowne Partners Austria. Dear Shareholders, we are very grateful for your continuous support of our efforts, and we are very confident that 2017 will turn out to be the best and most defining year in the history of MagForce. About MagForce AG and MagForce USA, Inc. MagForce AG, listed in the new Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(R) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc. NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries. For more information, please visit: www.magforce.com. Get to know our Technology: video (You Tube) Stay informed and subscribe to our mailing list. This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated. SOURCE: MagForce AG via the EQS Newswire distribution service including Press Releases and Regulatory Announcements


News Article | November 18, 2016
Site: marketersmedia.com

— The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Minimally Invasive Surgical (MIS) Devices pipeline products. Get Sample Report @ https://www.wiseguyreports.com/sample-request/729487-minimally-invasive-surgical-mis-devices-medical-devices-pipeline-assessment-2016 Scope - Extensive coverage of the Minimally Invasive Surgical (MIS) Devices under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Minimally Invasive Surgical (MIS) Devices and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry The report enables you to - - Formulate significant competitor information, analysis, and insights to improve R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of Minimally Invasive Surgical (MIS) Devices under development - Develop market-entry and market expansion strategies - Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline - In-depth analysis of the product’s current stage of development, territory and estimated launch date 1 Table of Contents 2 1.1 List of Tables 6 1.2 List of Figures 8 2 Introduction 9 2.1 Minimally Invasive Surgical (MIS) Devices Overview 9 3 Products under Development 10 3.1 Minimally Invasive Surgical (MIS) Devices - Pipeline Products by Stage of Development 10 3.2 Minimally Invasive Surgical (MIS) Devices - Pipeline Products by Territory 11 3.3 Minimally Invasive Surgical (MIS) Devices - Pipeline Products by Regulatory Path 12 3.4 Minimally Invasive Surgical (MIS) Devices - Pipeline Products by Estimated Approval Date 13 3.5 Minimally Invasive Surgical (MIS) Devices - Ongoing Clinical Trials 14 4 Minimally Invasive Surgical (MIS) Devices - Pipeline Products under Development by Companies 15 4.1 Minimally Invasive Surgical (MIS) Devices Companies - Pipeline Products by Stage of Development 15 4.2 Minimally Invasive Surgical (MIS) Devices - Pipeline Products by Stage of Development 17 5 Minimally Invasive Surgical (MIS) Devices Companies and Product Overview 18 5.1 Actuated Medical, Inc. Company Overview 18 5.1.1 Actuated Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 18 5.2 BriteSeed Company Overview 20 5.2.1 BriteSeed Pipeline Products & Ongoing Clinical Trials Overview 20 5.3 Delft University of Technology Company Overview 21 5.3.1 Delft University of Technology Pipeline Products & Ongoing Clinical Trials Overview 21 5.4 DistalMotion Company Overview 24 5.4.1 DistalMotion Pipeline Products & Ongoing Clinical Trials Overview 24 5.5 ES Vascular Ltd. Company Overview 26 5.5.1 ES Vascular Ltd. Pipeline Products & Ongoing Clinical Trials Overview 26 5.6 Ethicon Endo-Surgery, Inc. Company Overview 27 5.6.1 Ethicon Endo-Surgery, Inc. Pipeline Products & Ongoing Clinical Trials Overview 27 5.7 Eximis Company Overview 28 5.7.1 Eximis Pipeline Products & Ongoing Clinical Trials Overview 28 5.8 FlexDex Company Overview 29 5.8.1 FlexDex Pipeline Products & Ongoing Clinical Trials Overview 29 5.9 Fortimedix B.V. Company Overview 31 5.9.1 Fortimedix B.V. Pipeline Products & Ongoing Clinical Trials Overview 31 5.10 Hadassah Medical Center Company Overview 32 5.10.1 Hadassah Medical Center Pipeline Products & Ongoing Clinical Trials Overview 32 5.11 Human Extensions LTD Company Overview 33 5.11.1 Human Extensions LTD Pipeline Products & Ongoing Clinical Trials Overview 33 5.12 Imperial College London Company Overview 34 5.12.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 34 5.13 John Hopkins University Company Overview 35 5.13.1 John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 35 5.14 Osaka University Company Overview 36 5.14.1 Osaka University Pipeline Products & Ongoing Clinical Trials Overview 36 5.15 Rambam Health Care Campus Company Overview 37 5.15.1 Rambam Health Care Campus Pipeline Products & Ongoing Clinical Trials Overview 37 5.16 Signum Surgical Ltd Company Overview 38 5.16.1 Signum Surgical Ltd Pipeline Products & Ongoing Clinical Trials Overview 38 5.17 Technische Universiteit Eindhoven Company Overview 39 5.17.1 Technische Universiteit Eindhoven Pipeline Products & Ongoing Clinical Trials Overview 39 5.18 UltraSurge Technologies Ltd. Company Overview 40 5.18.1 UltraSurge Technologies Ltd. Pipeline Products & Ongoing Clinical Trials Overview 40 5.19 University of California, San Francisco Company Overview 41 5.19.1 University of California, San Francisco Pipeline Products & Ongoing Clinical Trials Overview 41 5.20 University of Wisconsin Madison Company Overview 45 5.20.1 University of Wisconsin Madison Pipeline Products & Ongoing Clinical Trials Overview 45 5.21 Varada Innovations Inc. Company Overview 47 5.21.1 Varada Innovations Inc. Pipeline Products & Ongoing Clinical Trials Overview 47 5.22 VenX Medical LLC Company Overview 48 5.22.1 VenX Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 48 5.23 XACT Robotics Ltd. Company Overview 51 5.23.1 XACT Robotics Ltd. Pipeline Products & Ongoing Clinical Trials Overview 51 6 Minimally Invasive Surgical (MIS) Devices- Recent Developments 52 6.1 Oct 26, 2016: LeMaitre Q3 2016 Record Sales $23.2 mm (+22%), Record Op. Income $5.3 mm (+61%) 52 6.2 Oct 26, 2016: Life Spine Achieves 32% Sales Growth and Announces Industry’s Largest Post-Packing Capabilities for Lateral Fusion 52 6.3 Oct 18, 2016: Intuitive Surgical Announces Third Quarter Earnings 53 6.4 Oct 17, 2016: Fortimedix Surgical Announces the U.S. Launch of symphonX Surgical Platform, the World’s Lowest Profile Single-Port Surgery Solution, During American College of Surgeons Clinical Congress 2016 54 6.5 Oct 17, 2016: Syneron Medical Strengthens Senior Management Team 54 6.6 Oct 17, 2016: Syneron Medical Announces Preliminary Third Quarter 2016 Revenue 55 6.7 Oct 10, 2016: Fortimedix Surgical Announces Successful Completion of First-In-Man Laparoscopic Cholecystectomy with FMX314, the World’s Lowest Profile Single-Port Surgery Solution, in the United States 55 6.8 Oct 03, 2016: Fortimedix Surgical Announces CE Mark Approval for FMX314, the World’s Lowest Profile Single-Port Surgery Solution 56 6.9 Oct 03, 2016: miVIP Reveals Robot-Assisted Gynecological Techniques to Surgeons Worldwide 56 6.10 Sep 30, 2016: MagForce Publishes Financial Results for the First Half of 2016 and Operative Highlights 57 For more information, please visit http://www.wiseguyreports.com

Loading MagForce collaborators
Loading MagForce collaborators